about
Are Basophils and Mast Cells Masters in HIV Infection?GM-CSF and IL-3 Modulate Human Monocyte TNF-α Production and Renewal in In Vitro Models of Trained Immunity.The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements.Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factorsThe oncolytic virus dl922-947 reduces IL-8/CXCL8 and MCP-1/CCL2 expression and impairs angiogenesis and macrophage infiltration in anaplastic thyroid carcinoma.The immune network in thyroid cancerHigh attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational studyOxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer.Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth.Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.T follicular helper (Tfh ) cells in normal immune responses and in allergic disorders.Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils.Mast cells in rheumatoid arthritis: friends or foes?Are Mast Cells MASTers in Cancer?Differential impact of high and low penetrance TNFRSF1A gene mutations on conventional and regulatory CD4+ T cell functions in TNFR1-associated periodic syndrome.Occurrence and significance of tumor-associated neutrophils in patients with colorectal cancer.Effect Of α2-Adrenergic Agonists And Antagonists On Cytokine Release From Human Lung Macrophages Cultured In Vitro.The Proteomic Landscape of Human Ex Vivo Regulatory and Conventional T Cells Reveals Specific Metabolic Requirements.Controversial role of mast cells in skin cancers.Human mast cells and basophils-How are they similar how are they different?Cellular subtype expression and activation of CaMKII regulate the fate of atherosclerotic plaque.Immunometabolic biomarkers of inflammation in Behçet's disease: relationship with epidemiological profile, disease activity and therapeutic regimensInnate Immune Modulation by GM-CSF and IL-3 in Health and DiseaseMast Cells, Angiogenesis and Lymphangiogenesis in Human Gastric Cancer.Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up studyElevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedemaEvaluation of vaccination safety in children with mastocytosisCancer Inflammation and CytokinesThe Role of Omalizumab in Patients With Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Comment on the Article by Jachiet et alProphylactic treatment with plasma-derived C1 inhibitor in idiopathic non-histaminergic angioedemaA Unique Case of Angioedema With Anti-C1 Inhibitor Antibodies and Normal C1 Inhibitor LevelsHereditary angioedema: the plasma contact system out of control: commentAutoimmune Endocrine Dysfunctions Associated with Cancer ImmunotherapiesThe Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint InhibitionMast Cells: Fascinating but Still Elusive after 140 Years from Their DiscoveryAnaplastic Thyroid Cancer Cells Induce the Release of Mitochondrial Extracellular DNA Traps by Viable Neutrophils
P50
Q30240071-A3A09F49-CE55-45CA-AB01-0EB91B8E6EE9Q30835058-293DA8A3-0918-4912-A4BA-D094895FDB01Q36596905-D3A982E1-E682-4431-AF29-54CCE851E153Q36676002-FA0D83A2-C3E3-42E0-A358-088E2EB5CB8AQ36738884-03C1EBFF-EBD8-4CCD-AE2E-42C11991F57AQ37079138-A94A2567-70B7-412E-B97C-13BDEB179B1CQ37299151-29C97F0F-D033-4F85-80DC-8E75C11421EDQ37353982-E3D81CC9-876D-4CC2-8364-00D222D3CB2DQ38607135-C088992F-F7D3-49A4-B6CE-B7EBFADC1B7AQ38731166-1F4EC29E-6247-48B7-B2C9-74DC82783E9DQ38771318-C72B8B9E-340E-4725-B254-FDC8034B57B9Q38811622-6D404BB6-1812-42B5-94D2-1E8AA3CE8C8CQ39243711-12535182-9332-46EE-A3BC-9A0306C77D85Q39265436-AE7BEAD0-75DE-406D-938A-11F5F3D3E5E9Q40129844-A1FF81A7-5E40-44DA-8F01-4CFCF0298345Q40873602-B063D713-241A-4C97-A2BE-949FF7D76AD6Q41860081-571721A4-2E0E-4695-8AAD-9E5D434389ACQ42378079-2A5ED438-79AE-4C02-8396-80E8C824BE14Q42494705-952B9AE3-D7D5-4045-9141-0B829387B197Q50068956-04C933C0-F396-4685-A4E9-77C356502F32Q50992407-417B3D1C-CDF3-4AC5-BB3A-DE12B16CF9B1Q58326000-F39634C4-36B4-44E1-B145-5B7A97068D98Q64255636-B56F9D19-648A-4D30-A537-347A913B4BC4Q64990427-AEE5C3DD-FB20-43B4-88D5-3752F7B4F662Q86175453-B5FD0DE9-9420-4DA6-8F73-55276AE0C42CQ87285114-5A9DD1FE-40E0-44C4-99EC-CD32174C8BB7Q88256648-D5EF23D3-00BC-47B5-964D-47D9F481C0A4Q88688308-919EFB12-5A12-4FC5-BED0-7A528A78D0CAQ89013932-A6A5C387-1121-4367-BD98-1EA9C898AA62Q89368772-267FE3C6-0058-4AAD-A63F-E16D6CD02070Q89406122-8CA9DEE8-1513-4AC1-8D2F-14F9D7A3209CQ91057086-4E4180A2-DC36-49E9-8A94-2F8FAD7266B2Q92349905-A35053A1-8724-42DB-B091-1600531F77DEQ92619376-FFD10425-182C-4E3E-A55C-06214F3C523DQ92661015-FE3EC654-257D-40FE-9D35-C31B49C256E3Q92782206-CBEF87E1-18AB-4F18-A94C-FCFC63E2AEC6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gianni Marone
@ast
Gianni Marone
@en
Gianni Marone
@es
Gianni Marone
@nl
type
label
Gianni Marone
@ast
Gianni Marone
@en
Gianni Marone
@es
Gianni Marone
@nl
prefLabel
Gianni Marone
@ast
Gianni Marone
@en
Gianni Marone
@es
Gianni Marone
@nl
P106
P31
P496
0000-0002-9849-4701